A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the first new schizophrenia drug mechanism approved in 50 years. Patients with strong negative symptoms responded best to the xanomeline–trospium combination, showing notable improvements in social behavior and mood.
